If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
James Rowley French (September 23, 1928 – December 20, 2017) was an American radio host, voice actor, writer and producer. French founded Imagination Theatre in 1996 and served as its producer until 2017. He was the morning DJ on the Seattle radio station KIRO from 1959 to 1971, and again from 1980 to 1994. As a voice actor, French was known for his work in video games by Valve, including Half-Life 2 (2004), Left 4 Dead (2008), and Dota 2 (2013).
Chlorpropamide and other sulfonylureas encourage weight gain, so they are generally not favored for use in very obese patients. Metformin (Glucophage) is considered a better drug for these patients. Sulfonylureas should be used with caution or generally avoided in patients with hepatic and renal impairment, patients with porphyria, patients who are breastfeeding, patients with ketoacidosis, and elderly patients.
Phenethylamine is a primary amine, the amino-group being attached to a benzene ring through a two-carbon, or ethyl group. It is a colourless liquid at room temperature that has a fishy odor, and is soluble in water, ethanol and ether. Its density is 0.964 g/ml and its boiling point is 195 °C. Upon exposure to air, it combines with carbon dioxide to form a solid carbonate salt. Phenethylamine is strongly basic, pKb = 4.17 (or pKa = 9.83), as measured using the HCl salt, and forms a stable crystalline hydrochloride salt with a melting point of 217 °C. Its experimental log P is 1.41.
Sources: en.wikipedia.org
Oxygen-containing compounds – are typically hydrophilic and polar, including materials such as silica gel, limestone (calcium carbonate), and zeolites. Carbon-based compounds – are typically hydrophobic and non-polar, including materials such as activated carbon and graphite. Polymer-based compounds – are polar or non-polar, depending on the functional groups in the polymer matrix.
=== General properties === The primary encoded protein of C1orf27 consists of 454 amino acid residues and is 3926 base pairs long. It consists of 14 total exons. The predicted molecular weight of the primary, unmodified protein is approximately 51.1 kDa.
On the time scale of continuous chromatography runs, it is fairly common to observe changes in important process parameters, such as column health, buffer quality, feed titer (concentration) or feed composition. Such changes result in an altered maximum column capacity, relative to the amount of loaded feed material. In order to achieve a steady quality and yield for each process cycle, the timing of the individual process steps therefore has to be adjusted. Manual changes are in principle conceivable, but rather impractical. More commonly, dynamic process control algorithms monitor the process parameters and apply changes as needed automatically. There are two different operating modes for dynamic process controllers in use today (see Figure on the right). The first one, called DeltaUV, monitors the difference between two signals from detectors situated before and after the first column. During initial loading, there is a large difference between the two signals, but it is diminishing as the impurities make their way through the column. Once the column is fully saturated with impurities and only additional product is being held back, the difference between the signals reaches a constant value. As long as the product is completely being captured on the column, the difference between the signals will remain constant. As soon as some of the product breaks through the column (compare above), the difference diminishes. Thus, the timing and amount of product breakthrough can be determined.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.